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Abstract
Background: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium
tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and
immunogenicity of this new vaccine in West African volunteers.
Methods and Findings: We vaccinated 21 healthy adult male subjects (11 BCG scar negative and 10 BCG scar positive) with
MVA85A after screening for evidence of prior exposure to mycobacteria. We monitored them over six months, observing for
clinical, haematological and biochemical adverse events, together with assessment of the vaccine induced cellular immune
response using ELISPOT and flow cytometry. MVA85A was well tolerated with no significant adverse events. Mild local and
systemic adverse events were consistent with previous UK trials. Marked immunogenicity was found whether individuals
had a previous BCG scar or not. There was not enhanced immunogenicity in those with a BCG scar, and induced T cell
responses were better maintained in apparently BCG-naı¨ve Gambians than previously studied BCG-naı¨ve UK vaccinees.
Although responses were predominantly attributable to CD4+ T cells, we also identified antigen specific CD8+ T cell
responses, in subjects who were HLA B-35 and in whom enough blood was available for more detailed immunological
analysis.
Conclusions: These data on the safety and immunogenicity of MVA85A in West Africa support its accelerated development
as a promising booster vaccine for tuberculosis.
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Introduction
Tuberculosis (TB) causes approximately 2 million deaths
annually; most of these occur in developing countries[1]. The
only available vaccine, BCG, is widely used in developing
countries. It reduces the incidence of tuberculous meningitis and
disseminated TB in childhood, but has variable efficacy against
pulmonary TB[2,3]. A major hypothesis regarding the poor
efficacy of BCG vaccination in developing countries is that intense
exposure to environmental mycobacteria reduces the immunoge-
nicity and efficacy of BCG[4,5].
We have developed a prime-boost strategy that seeks to
overcome this limitation[6]. It is based on the striking effect of
non-replicating poxviruses on the amplification of pre-existing T
cell responses[7–9]. Expressing a major secreted antigen of M.
tuberculosis (antigen 85A) in the non-replicating modified vaccinia
viral vector (MVA) strongly boosts BCG primed T cell responses
in several species, including humans. Importantly, BCG-MVA85A
prime-boost regimens have greater protective efficacy than BCG
alone in several animal models of TB, including non-human
primates.[10,11](Verreck et al, manuscript submitted)
We have reported the immunogenicity of MVA85A in UK
volunteers[12,13]. The T cell responses observed are the highest
reported for any subunit vaccine against any disease. Responses
were highest in those primed with BCG, but even those subjects
not primed had stronger T cell responses than seen with other
vaccine candidates. This is thought to relate to prior exposure to
environmental mycobacteria and induction of central memory T
cell responses, which are then boosted with MVA85A [12]. In
view of the attenuated immunogenicity of BCG in Africa and
reports that many other novel vaccines had reduced immunoge-
nicity in developing countries compared to the country-of-
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origin,[14–16] we assessed MVA85A in The Gambia at an early
stage of its clinical development. Here we report the safety and
immunogenicity results from this trial.
Methods
Study setting and recruitment
The protocols for this trial and the supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocols S1 and S2. The study was conducted in Banjul,
between 2003 and 2005, in an area housing approximately
600,000 people. The study setting and the inclusion and exclusion
criteria have been described previously[17]. The study protocol
(GM 920) was approved by the Gambia government/MRC (SCC
920) and Oxfordshire Tropical Research Ethics committees
(OxTREC 006-03). After written informed consent, interview,
and clinical examination (males aged 18 to 45 years), blood
samples were collected for ELISPOT, haematology and biochem-
istry, and HIV and HBV antibody tests. HIV positive subjects
were referred to the MRC HIV clinic, where free anti-retroviral
treatment is available. Each subject had a chest X-ray read by two
specialist physicians, and a PPD skin test (2TU PPD RT23, SSI,
Copenhagen, Denmark) read by a trained field worker at 48–
72 hours. We aimed to deliver MVA85A to volunteers with
incrementally increasing evidence of prior mycobacterial expo-
sure. The first arm of the trial enrolled BCG scar negative, and the
second arm BCG scar positive, individuals. The severity of local
and systemic adverse events was classified using standard criteria,
as previously used in the UK studies with this vaccine.
Vaccination and follow-up
Those eligible were vaccinated within 8 weeks of screening. Five
were vaccinated in the BCG negative arm before enrolment into
the BCG positive arm began. On the vaccination day they had a
clinical evaluation and provided a blood sample. The vaccine was
administered intra-dermally over the insertion of the left deltoid
muscle, at a dose of 56107 plaque forming units (pfu) of MVA85A
(135 ml). A second vaccination was given 3 weeks later to the BCG
scar negative vaccinees, in the right deltoid muscle. Subjects were
observed for one hour following immunisation and vital signs were
recorded. They were then seen on day one and two. Follow-up
visits were made (Figure 1) to enquire about possible adverse
events and any medications taken. All signs and symptoms were
recorded. On each of the vaccination and follow-up days, blood
was obtained for immunological assays; haematological and
biochemical analyses were repeated on days 7 and 84.
ELISPOT screen and Immunogenicity
We used an IFN-c ELISPOT assay to screen volunteers at
recruitment and monitor the immunogenicity of MVA85A, as
previously described[18]. Briefly, PBMCs were plated at 36105
cells/well. Sequential peptides (15mers overlapping by 10)
spanning the length of ESAT-6 and CFP-10, were used in pools
at 2.5 mg/ml (ABC, Imperial College, London, UK). M. tuberculosis
purified protein derivative (RT49, SSI, Copenhagen, Denmark;
PPD-T) was used at 5 mg/ml. ELISPOT plates were incubated
overnight at 37uC. For the BCG scar negative group, positive wells
were pre-defined to contain at least 30 Spot Forming Units/
million cells (SPM) more than, and at least twice as many as,
negative control wells for these antigens. Following the UK trials, a
much stronger response to vaccination was expected in the BCG
primed group. Therefore, positive wells were pre-defined to
contain at least 10 SPM more than, and at least twice as many as,
negative control wells. After acceptable safety data were obtained
in BCG scar negative group, the PPD ELISPOT screening
criterion was relaxed to at least 100 SPM.
To monitor Ag85A immunogenicity we used the ELISPOT
response to a sum of 66 pooled peptides (7 pools of 6–10 peptides).
This method will count twice a T cell that responds to any of the
10-mer overlap regions that occur in two pools with adjacent
peptides. To monitor individual peptide responses we used Ag85A
peptide pools in different combinations so that an individual
peptide response would be clearly identifiable when two pools with
the same peptide responded within a matrix. We used recombi-
nant Ag85A protein (Leiden University), and PPD-T. ELISPOT
plates were counted using an automated ELISPOT reader (AID-
GmbH, Germany) with correction for artefacts. The positive
control was Phytohaemaglutinin (PHA; Sigma-Aldrich, UK). All
antigens were tested in duplicate wells.
Figure 1. Timeline for vaccination and blood sampling schedules. A. BCG scar negative subjects. B. BCG scar positive subjects.
doi:10.1371/journal.pone.0002921.g001
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CD4+ and CD8+ T cell activation as measured by CD69
expression
An aliquot of whole blood (200 ml) was harvested after 20 h of
culture at 37uC alone or stimulated with 5.0 mg/ml Ag85A
peptide pool, 2.0 mg/ml PPD-T and 10 mg/ml PHA. After
incubation, cells were stained for 30 min at room temperature
with a monoclonal antibody cocktail mix containing anti-CD4
FITC, anti-CD69 PE, anti-CD8 PerCP and anti-CD3 APC (BD
Biosciences, UK). Red blood cells were lysed and lymphocytes
washed, fixed in 2% p-formaldehyde and acquired with a Cell
Quest software by live gating on CD3+ T cells (50000 events) on a
four-colour flow cytometer (BD FASCalibur, BD Biosciences,
UK). Analyses were carried out using FlowJo software (Treestar
Inc., San Carlos, CA).
CD8+ T cell lines
Cryopreserved PBMC were thawed, washed and re-suspended at
26105/well in a 96 U well microtitre plate with p23 peptide (10 mg/
ml) in RPMI-1640 supplemented with 5% AB serum, L-glutamine
2mM and antibiotics. On the 3rd and 7th days IL-2 (20 IU/ml) was
added. The expanded lymphocytes were harvested, washed, re-
stimulated with p23 (10 mg/ml), PHA (10 mg/ml) or medium alone
in separate tubes in the presence of Brefeldin A (10 mg/ml) for six
hours. Cells were harvested and washed with FACs buffer (PBS,
2mM EDTA and 1%BSA) lysed with BD FACSTM Lysing Solution.
Cells were then washed and permeabilized with BD FACS
Permeabilizing Solution. After an additional wash, cells were
divided into two tubes. Surface and intracellular staining antibodies
(anti human, CD4-PE, CD69-PerCP, CD3-APC and IFN-c -FITC)
in tube 1 and anti human (CD8-PE, CD69-PerCP, CD3-APC and
IFN-g-FITC) in tube 2 were added in a single staining step. Finally,
the cells were washed and fixed for flow cytometric analysis.
Peptide stimulation
The Ag85A HLA-B35 restricted CD8+ epitope MPVGGQSSF
(ABC, Imperial College, London, UK ) was used to stimulate the
cryopreserved PBMC isolated on day 7 after vaccination in an ex
vivo ELISPOT assay. Recovered cells were rested in medium
containing 5% human AB serum for at least 2 hours before being
washed and set up in an ELISPOT assay with the CD8+ epitope.
Data management and statistical analysis
All data were either double entered, or electronically trans-
ferred, into an ACCESS database and manually validated.
ELISPOT counts were corrected for the background in the
negative control well. Those beyond the upper limit of detection of
the ELISPOT reader were arbitrarily given a count of 500 spots/
well. All comparisons were within subject and were performed
using a Wilcoxon matched pairs test.
Results
Screening
We screened 240 subjects to identify 10 to 12 individuals for each
arm of the study. Some subjects showed transient ESAT-6/CFP-10
ELISPOT positivity after enrolment, consistent with fluctuations in
responses to these antigens seen in other Gambian studies[19].
Therefore, a re-screen ELISPOT was conducted on the day before
vaccination for subjects in the BCG scar positive group.
Safety of MVA85A
Overall, 21 volunteers were enrolled and 31 doses of MVA85A
were administered. One subject in the BCG scar negative group
did not receive the second vaccination because he became ESAT-
6 ELISPOT positive on day 7. On subsequent assays this reverted
to negative. No significant changes occurred in vital signs during
the one-hour post-vaccination observation or follow-up periods.
There were minimal reports of any systemic side effects;
specifically no symptoms of a flu-like illness or lymphadenopathy.
One subject had a mild headache and diarrhoea in the first
24 hours after vaccination, both resolved quickly. No other reports
or documentation of headache, myalgia, fever, or malaise were
made. Table 1 shows the local signs and symptoms that were
encountered. Induration at the injection site was almost universal
and the majority had at least one other symptom or sign. None
reported limitation of arm movements or the need to refrain from
certain activities due to pain. The skin was not warmer than the
surrounding regions. One volunteer still had tenderness at the site
of the first vaccination at four weeks. This was elicited by firm
pressure. Discolouration and scaling, when present, disappeared
by day 28 in all subjects. There were no significant laboratory
abnormalities. There were no differences in either the local or
systemic adverse event profiles between the BCG scar positive and
BCG scar negative subjects.
Immunogenicity of MVA85A in BCG Scar negative
vaccinees
11 BCG scar negative subjects were immunised with MVA85A
(Figure1A). There was a high degree of variability between
individuals in the vaccine induced immune responses; these data
are shown as median ELISPOT frequencies in Figure 2A and the
inter-quartile ranges are shown in Table 2. The ELISPOT
responses one week after vaccination reached or exceeded the
maximal readily quantified level for the majority (60%) of subjects.
The increase in ELISPOT response at one week was highly
significant for Ag85A peptides (p = 0.002), Ag85A protein
(p = 0.004), and PPD-T (p,0.001).
After the first week, the response contracted to a stable plateau
frequency, higher than before vaccination, which was maintained
until the end of the trial. The frequency of the Ag85A ELISPOT
response to peptides at the end of the trial was significantly higher
than the frequency at the start (p = 0.004). A consistent hierarchy
of responses to antigens was found in a predictable order, from
highest to lowest: summed pooled peptides, Ag85A, and PPD-T. It
was not possible to accurately quantify differences at the peak of
Table 1. Clinical outcomes at the injection sites after
vaccination with MVA-85A.
Adverse Event Dose 1 (n=21) Dose 2 (n=10)
Discolouration, median
(range) mm
4 (5–14) 0 (0) a
1(3)b
Pain 11 1a
2b
Induration 20 9a
7b
Scaling 13 0a
7b
The data were recorded over seven days after each vaccination
n: number of volunteers vaccinated and followed up
afirst vaccination site
bresidual change at the second vaccination site
doi:10.1371/journal.pone.0002921.t001
MVA85A Vaccine Trial in Africa
PLoS ONE | www.plosone.org 3 August 2008 | Volume 3 | Issue 8 | e2921
response, as many were beyond the upper limit of detection.
However the original hierarchy was maintained as the response
waned. A second MVA85A vaccination given 3 weeks after the
first did not boost the ELISPOT response further, consistent with
the UK trials [12].
Immunogenicity in BCG Scar positive vaccinees
On the basis of the data from the BCG scar negative subjects,
where there was no significant increase in the immune response to
a second vaccination, it was decided that the second immunisation
with MVA85A at week 3 should be omitted in the BCG scar
positive group (Figure 1B). An extra visit at Day 14 was added to
monitor immunogenicity. The schedules in the two groups were
otherwise comparable. The profile and hierarchy of response to
antigens were similar to the BCG scar negative group (data not
shown): the immunogenicity of Ag85A (Figure 2B; Table 2) was
similar, with most of the subjects showing a maximal response one
week after vaccination (day 7). As with the BCG scar negative
group, the ELISPOT frequencies were significantly higher on day
7 after vaccination than the responses at the start of the trial for
Ag85A peptides (p = 0.002), Ag85A protein (p = 0.002) and PPD-T
(p,0.001). Unexpectedly, three subjects achieved a maximal
response at day 14, in contrast to the expected 7 day peak time
point, but in the absence of a day 14 sample in the BCG scar
negative group, a formal comparison was not possible. Peptide
responses were broad and spanned the length of antigen 85A.
Responses to peptides p9, p13, p24 and p28 were most frequently
observed (data not shown), consistent with the UK trials [12].
Figure 2. Median Ex-vivo interferon-gamma ELISPOT responses to Ag85A protein, PPD-T and Ag85A overlapping peptides after
MVA85A vaccination in healthy male volunteers. A. BCG scar negative vaccines (n = 11); B. BCG scar positive vaccinees (n = 10).
doi:10.1371/journal.pone.0002921.g002
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CD69 expression on antigen specific CD4+ and CD8+ T
cells
We stimulated the whole blood of 3 volunteers with all 66
Ag85A peptides and monitored the proportion of CD4+ and
CD8+ cells activated by upregulation of expression of CD69
(Table 3). A high proportion of both CD4+ and CD8+ cells were
activated one week following vaccination at frequencies higher
than might have been estimated from the IFN-c ELISPOT
frequencies (2,200–2,800 SPM).
Identification of CD8+ T cell responses
To understand responding phenotypes in more detail we looked
for unambiguous peptide pool responses, consistent with a single
epitope being maintained throughout the entire monitoring
period. After analysing all peptide pool responses we identified a
single epitope in 2 subjects, which was due in both cases to the
response to a single peptide (p23). Short term cell lines to p23 were
generated with PBMC recovered 28 days after vaccination, and
the CD4/CD8 phenotype was analysed by IFN-c ICS. For one
subject (volunteer 1), both CD4 and CD8 p23 specific responses
were identified (Figure 3A), while an exclusive CD8 response was
found for the second subject (volunteer 2; Figure 3A). Volunteer 2
also showed CD8 activation by CD69 expression after stimulation
with pooled Ag85A peptides 28 days after vaccination (Figure 3B).
Confirmation of dominant HLA-B35 CD8+ T cell response
An HLA-B*3501 (abbreviated to HLA-B35) class I restricted CTL
epitope within Ag85A p23 sequence had previously been reported in
The Gambia[20] and HLA-B35 is also a common allele in this
population[21]. We confirmed by PCR that two subjects were
positive for the HLA-B35 allele. Both of these subjects responded with
levels of 90 and 110 SPM, respectively, with PBMC recovered one
week post vaccination, but no response prior to vaccination. The data
confirm that both subjects had vaccine-induced HLA-B35 restricted
CD8+ T cells specific for a previously identified Ag85A epitope.
Discussion
We report the first trial of a new generation TB vaccine in
Africa. MVA85A was administered intra-dermally to two groups
of volunteers with increasing evidence of prior mycobacterial
exposure. The vaccine was found to be safe in these volunteers,
enabling further studies to proceed in larger numbers of
individuals to fully evaluate the adverse event profile and
frequency. Since safety was demonstrated in these trials in The
Gambia, further trials with this vaccine in TB endemic areas in
individuals more representative of the general population,
Table 2. Median and inter-quartile range of ELISPOT responses for Ag85A protein, PPD-T and Ag85A overlapping peptides at each
time point.
ELISPOT count (Median & inter-quartile range; SPMa PBMCb)
Ag85A PPD-T Ag85A peptides
BCG scar – day lower quartile median upper quartile lower quartile median upper quartile lower quartile median upper quartile
0 5 10 42 43 89 208 57 79 131
7 296 1625 1645 236 526 1381 1001 1704 3843
21 74 307 531 96 157 453 424 943 1559
28 73 264 1353 77 170 472 263 761 1704
49 40 160 404 76 121 162 253 418 1545
77 80 97 166 78 111 166 144 422 1102
105 33 61 116 49 74 121 123 281 502
180 40 118 183 79 167 210 142 294 924
BCG scar + 0 3 7 26 28 79 94 26 53 89
7 224 367 475 149 191 422 558 1120 2049
14 99 228 647 168 286 617 515 825 1960
28 43 199 348 71 235 307 92 564 1219
60 35 64 264 50 155 191 228 276 661
90 12 64 134 36 80 157 108 144 377
180 44 67 151 88 116 183 151 282 449
aSPM, Spot Forming Units/million.
bPBMC, Peripheral Blood Mononuclear Cells
doi:10.1371/journal.pone.0002921.t002
Table 3. CD69 expression in Antigen 85A specific, CD4+ and
CD8+ T cells.
Proportion of CD69 expression
Experiment number Day 0 Day 7 Day 49
CD8+ cells
1 0.00 0.22 0.56
2 ND 0.28 0.02
3 0.00 0.24 0.02
CD4+ cells
1 0.04 0.27 1.84
2 ND 1.95 0.00
3 0.05 1.09 0.11
Frequencies of positive cells are given as a percentage of the total gated
lymphocytes.
doi:10.1371/journal.pone.0002921.t003
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including subjects latently infected with M. tuberculosis, have
commenced. This vaccine was found to be highly immunogenic
in the studies reported here, inducing exceptionally high
frequencies of antigen specific CD4+ T cells as well as some
antigen specific CD8+ T cells.
The peak responses to vaccination with MVA85A, in the UK and
The Gambia, are the highest reported for any subunit vaccine in
humans, at least using ELISPOT assays[22] [9]. The induced T cell
responses are broad, target multiple epitopes and are predominantly
CD4+. Although MVA85A was known to induce CD4+ T cell
mediated immunity, we now show that it also induces detectable
CD8+ T cell responses, in the few subjects we were able to study in
detail in this trial. Since CD8+ T cells were documented by focusing
on peptide responses that persist throughout the trial period, it will be
important to determine whether ELISPOT responsive CD8+ T cells
survive longer than their CD4+ counterparts, as has been suggested
[23]. Several reports have provided evidence for some protective role
of classical CD8+T cells in TB, at least in murine models, so this is an
important finding [24–26]. If CD8+ T cells are found to be generally
more readily induced by MVA85A in Africa than the UK, we
speculate that this may relate to differential priming by environmental
mycobacteria in the two settings. We were only able to perform the
peptide mapping in a very limited number of subjects due to
restrictions in the volume of blood we were permitted to take. In
addition, only two subjects were found to be HLA B35 positive, and
we were therefore only able to look for responses to the B35 restricted
CD8+ T cell epitope in them. Further, more detailed, work in the
expanded ongoing trials is needed to confirm the presence of CD8+T
cell responses induced by MVA85A in TB endemic areas.
The lack of any boosting effect seen with the second MVA85A
vaccination mirrors the findings of the UK trial.[12] It is likely that
the lack of boosting at such a short interval is due to anti-vector
immunity–which may be B and/or T cell mediated. Interestingly,
a study in the Gambia with a recombinant MVA expressing a
malaria antigen, showed that it was possible to boost responses
with a second MVA to the same magnitude as the first, with an
interval of one year between vaccinations.[27] This has important
implications for the increasing use of this vector as a vaccine for a
number of pathogens, and further work is needed to define the
nature and duration of the anti-vector immunity.
Unlike the MVA85A trial in the UK,[12] there was no significant
difference in the immunogenicity between BCG scar positive and
BCG scar negative groups in The Gambia. It appears possible that a
greater exposure of Gambians to environmental mycobacteria
compensates for the lack of a BCG immunisation. Therefore, a
BCG priming immunisation may be most important in young
children. It should be noted that the absence of a BCG scar is not a
fully reliable indicator of the lack of earlier vaccination[28,29].
An interesting difference is observed between the plateau level of
T cell response in the Gambian vaccinees and in subjects receiving
the same vaccine in the UK. While the peak responses were little
different, the plateau response in BCG naı¨ve Gambians of over 200
SPM to antigen 85A peptides was higher than that observed in the
UK (median 105 SPM). Whether this relates to higher pre-
vaccination levels of central memory cells in Gambians, or more
frequent low level boosting by recurrent exposure to low doses of
environmental mycobacteria in Africa, requires further study.
Whilst we went to significant efforts to ensure that the first
volunteers were as mycobacterially naı¨ve as possible, it is likely that
most if not all individuals had been exposed to mycobacteria
before[30]. The discovery of a transient ESAT-6/CFP-10 ELI-
SPOT response was unexpected but suggests there is a consistent
low background of mycobacterial exposure in the community. The
PPD skin test is a particularly sensitive, and surprisingly specific,
indicator of recent M. tuberculosis infection in The Gambia [31,32]
and it is possible that some of the transient ESAT-6/CFP-10
response may be due to an uncharacterised environmental
mycobacterial infection–certain environmental mycobacteria,
such as M. marinum, express these two antigens [33,34] and are
commonly encountered in The Gambia.
In conclusion, MVA85A appears safe and highly immunogenic
in Africa. The data from this study support accelerated
development of this candidate towards a large scale efficacy trial
in Africa and subsequent licensure. Further phase I and II trials
are now in progress in a South African population and a phase II
trial in Gambian infants is also underway.
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